Stocks CNBC 2h ago

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Market Intelligence Analysis

AI-Powered
Why This Matters

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.

Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."

Continue Reading
Full article on CNBC
Read Full Article

Related Articles

Stocks 30m ago

True Anomaly raises $650 million to support space interceptors for Trump's Golden …

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Stocks 42m ago

A second China shock is hitting Europe. These stocks are most vulnerable, …

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Stocks 43m ago

Citi UK CEO: 'Phenomenal' market resilience is keeping recession risk at bay …

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Stocks 56m ago

U.S. is 'being humiliated by Iran,' says Germany's Merz, as Europe's patience …

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Stocks 1h ago

Treasury yields rise as U.S.-Iran peace talks hit an impasse

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Stocks 4h ago

Oil major BP beats profit expectations as Iran war boosts fuel prices

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Original article published by CNBC on April 28, 2026.
Analysis and insights provided by AnalystMarkets AI.